Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
申请人:——
公开号:US20040024066A1
公开(公告)日:2004-02-05
Compounds of formula (I):
1
R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and
R
1
is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.
Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R
1
is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.
1
Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides
申请人:Best John Desmond
公开号:US20050288376A1
公开(公告)日:2005-12-29
Compounds of formula (I):
R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and
R
1
is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.
AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
申请人:Janssen Pharmaceutica NV
公开号:US20130102585A1
公开(公告)日:2013-04-25
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:
wherein Y, Z, R
1
, and s are defined herein.